dc.creator | Cauce, Alejandro | es |
dc.creator | Briales, Alejandra | es |
dc.creator | Rodríguez Rojas, Alexandro | es |
dc.creator | Costas, Coloma | es |
dc.creator | Pascual Hernández, Álvaro | es |
dc.creator | Blázquez, Jesús | es |
dc.date.accessioned | 2017-07-27T11:37:43Z | |
dc.date.available | 2017-07-27T11:37:43Z | |
dc.date.issued | 2012-05-01 | |
dc.identifier.citation | Cauce, A., Briales, A., Rodríguez Rojas, A., Costas, C., Pascual Hernández, Á. y Blázquez, J. (2012). Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: Mura confers clinical resistance at low fitness cost. Antimicrobial Agents and Chemotherapy, 56 (5), 2767-2769. | |
dc.identifier.issn | 0066-4804 (impreso) | es |
dc.identifier.issn | 1098-6596 (electrónico) | es |
dc.identifier.uri | http://hdl.handle.net/11441/63338 | |
dc.description.abstract | To determine whether the overexpression of chromosomal genes can confer fosfomycin resistance, genomewide screening of a complete set of 5,272 plasmid-expressed open reading frames of Escherichia coli (ASKA collection) was performed. Major results are that (i) no clinical level of resistance is achieved by overexpressing chromosomal genes, except murA; (ii) this level is reached at a low fitness cost; and (iii) this cost is much lower than that imposed by other mutations conferring fosfomycin resistance. | es |
dc.description.sponsorship | Ministerio de Ciencia e Innovación y Instituto de Salud Carlos III PI10/00105 | es |
dc.description.sponsorship | Spanish Network for Research on Infectious Diseases REIPI RD06/0008 | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | American Society for Microbiology | es |
dc.relation.ispartof | Antimicrobial Agents and Chemotherapy, 56 (5), 2767-2769. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: Mura confers clinical resistance at low fitness cost | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Microbiología | es |
dc.relation.projectID | PI10/00105 | es |
dc.relation.projectID | REIPI RD06/0008 | es |
dc.relation.publisherversion | http://dx.doi.org/10.1128/AAC.06122-11 | es |
dc.identifier.doi | 10.1128/AAC.06122-11 | es |
idus.format.extent | 3 p. | es |
dc.journaltitle | Antimicrobial Agents and Chemotherapy | es |
dc.publication.volumen | 56 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 2767 | es |
dc.publication.endPage | 2769 | es |
dc.contributor.funder | Ministerio de Ciencia e Innovación (MICIN). España | |